



PRESS RELEASE

FOR IMMEDIATE DISCLOSURE

ORTHO REGENERATIVE TECHNOLOGIES SECURES DTC ELIGIBILITY FOR THE TRADING OF ITS SHARES ON THE US OTCQB MARKET

Montreal, QC, March 31, 2021 – [Ortho Regenerative Technologies Inc.](#) (CSE: ORTH, OTCQB: ORTIF) (“Ortho RTI” or the “Company”), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States.

“Securing DTC eligibility is an important step of our strategy to facilitate the trading of our common shares for U.S investors and brokerage firms. This will allow for faster execution and improved liquidity, which in turn will help with broadening our investor base”, said Claude LeDuc, Ortho RTI’s President and CEO.

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

About Ortho Regenerative Technologies Inc.

Ortho RTI is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. Ortho-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. A multi-

site US Ortho-R Rotator Cuff Tear Repair Pilot Phase I/II clinical trial is being planned and organized. In parallel, an FDA IND submission is planned for Q1-2021. Considering the significant potential of our technology platform, Ortho RTI continues to assess new therapeutic target uses outside of the soft tissue repair field. Further information about Ortho RTI is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com. Also follow us on LinkedIn and Twitter.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For further information, please contact:

Claude LeDuc,

President and Chief Executive Officer

(514) 651-1282

leduc@orthorti.com

or

Frederic Dumais,

Director Communications and Investor Relations

(514) 782-8803

dumais@orthorti.com

or

Mike Cavanaugh

Managing Director, Westwicke Partners

617-877-9641

Mike.cavanaugh@westwicke.com